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ABSTRACT
Background
Pulmonary hypoplasia and persistent pulmonary hypertension account for significant
mortality and morbidity in neonates with congenital diaphragmatic hernia (CDH). Global lung
immaturity and studies in animal models suggest the presence of surfactant deficiency that
may further complicate the pathophysiology of CDH. However, data about surfactant status in
human fetuses with CDH at birth are contradictory. The lack of a chronological study of
surfactant content in late pregnancy has been a significant limitation. The appropriateness of
administering surfactant supplements to neonates with CDH is therefore a debated question.
Methods and Findings
We investigated surfactant content in human fetuses with CDH compared to age-matched
fetuses with nonpulmonary diseases used as controls. Concentrations of disaturated
phosphatidylcholine and surfactant proteins were found to be similar at a given stage of
pregnancy, with both components showing a similar pattern of increase with progressing
pregnancy in fetuses with CDH and in control fetuses. Thyroid transcription factor 1, a critical
regulator of surfactant protein transcription, similarly displayed no difference in abundance.
Finally, we examined the expression of three glucocorticoid-regulated diffusible mediators
involved in lung epithelial maturation, namely: keratinocyte growth factor (KGF), leptin, and
neuregulin 1 beta 1 (NRG1-b1). KGF expression decreased slightly with time in control fetuses,
but remained unchanged in fetuses with CDH. Leptin and NRG1-b1 similarly increased in late
pregnancy in control and CDH lungs. These maturation factors were also determined in the
sheep fetus with surgical diaphragmatic hernia, in which surfactant deficiency has been
reported previously. In contrast to the findings in humans, surgical diaphragmatic hernia in the
sheep fetus was associated with decreased KGF and neuregulin expression. Fetoscopic
endoluminal tracheal occlusion performed in the sheep model to correct lung hypoplasia
increased leptin expression, partially restored KGF expression, and fully restored neuregulin
expression.
Conclusions
Our results indicate that CDH does not impair surfactant storage in human fetuses. CDH
lungs exhibited no trend toward a decrease in contents, or a delay in developmental changes
for any of the studied surfactant components and surfactant maturation factors. Surfactant
amounts are likely to be appropriate to lung size. These findings therefore do not support the
use of surfactant therapy for infants with CDH. Moreover, they raise the question of the
relevance of CDH animal models to explore lung biochemical maturity.
The Editors’ Summary of this article follows the references.
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Congenital diaphragmatic hernia (CDH) is a developmental
abnormality that affects one in 2,500–5,000 live births,
depending on the studies, and accounts for 8% of all major
congenital anomalies. CDH restricts fetal lung development.
The resulting lung hypoplasia and hypertension have
dramatic consequences at birth, and the disease continues
to cause high rates of mortality and morbidity despite recent
progress in neonatal care [1,2]. Data from human fetuses with
CDH, as well as data from animal models, indicate global lung
immaturity with respect to fetal age, including reduced
bronchial branching, decreased acinar complexity, thickened
septa, and reduced vascularization [3]. Although this concept
is debated, lung immaturity in CDH has also been suggested
to involve the surfactant system.
Pulmonary surfactant, which is a lipid–protein complex
produced by alveolar type II (ATII) cells, prevents alveolar
collapse during the breathing cycle by reducing surface
tension at the air–liquid interface [4]. Surfactant deﬁciency,
the principal cause of which is premature birth, results in
neonatal respiratory distress. The major component of
surfactant is a surface-active phospholipid, disaturated
phosphatidylcholine (DSPC). Four characteristic surfactant
proteins (SPs) include the collectins SP-A and SP-D, which
play a role in innate immunity and regulate surfactant
homeostasis [5], and the hydrophobic proteins SP-B and SP-
C, which augment the surface properties of phospholipids [6].
During fetal development, the production of surfactant is not
abundant until late pregnancy. The developmental regulation
of surfactant synthesis includes both hormonal control and
mesenchymal–epithelial interactions [7]. Under glucocorti-
coid stimulation, fetal lung ﬁbroblasts release factors that
promote ATII cell maturation [8]. Three diffusible mediators,
including ﬁbroblast growth factor 7 (also known as keratino-
cyte growth factor [KGF]) [9,10], leptin [11], and neuregulin 1
beta 1 (NRG1-b1) [12,13] have recently been proposed to
mediate this stimulating activity.
The prevailing opinion that the CDH lung is surfactant
deﬁcient is principally based on the immature morphological
aspect of the parenchyma and on reports of diminished
surfactant content in animal models of CDH. The surfactant
system has been repeatedly reported to be deﬁcient in two
classical models of CDH, the surgically created diaphragmatic
hernia (sDH) in the fetal sheep [14–17] and the nitrofen
model in the rat fetus [18–20]. This conclusion was based on a
variety of determinations, including tissue and lavage-ﬂuid
phospholipids, lavage-ﬂuid SPs, tissue SP and SP-transcript
levels, and dynamic surface-tension measurement. However,
conﬂicting results have been published indicating no change
in alveolar surfactant composition [21], unchanged or even
increased SP expression with a higher proportion of cells
expressing SP in the nitrofen model [22,23], and increased SP
expression in the ovine model [24].
Controversy persists regarding whether or not human
infants with CDH are surfactant deﬁcient. Whereas some
studies concluded that surfactant components failed to
increase in amniotic ﬂuid [25], or that alveolar SP-A and
DSPC were decreased 75% and 50%, respectively, despite a
normal rate of DSPC synthesis [26,27], others reported no
signiﬁcant change in amniotic ﬂuid [28] or lung lavage ﬂuid
[29] phospholipids. Immunohistochemical detection of SP-A
indicated weak labeling and a reduced proportion of positive
cells, suggesting the possibility of delayed ATII cell matura-
tion [30]. The controversy over surfactant deﬁciency is likely
to have arisen from a variety of causes, including the use of
various methodological approaches arriving at different
conclusions, and the use of different therapeutic practices.
First, a variety of biological materials have been explored,
including amniotic ﬂuid [25,28], tracheal aspirates [26], and
lavage ﬂuid [29], and different maturity tests with debatable
values have been used, including evaluation of DSPC [25,26],
lecithin-to-sphingomyelin ratio, and levels of phosphatidyl-
glycerol [26,27] and SPs [26,30]. Second, it is possible that
changes were induced by prenatal exposure to glucocorti-
coids [31] or by neonatal care methods (e.g., ventilation and
extracorporeal membrane oxygenation) [26]. Third, there is a
paucity of studies of CDH human lung tissue that might have
helped to resolve the question.
Clarifying this question is important insofar as decisions
have to be made as to whether or not infants with CDH
should be supplemented with surfactant at birth [32–34]; this
issue is particularly important because the use of exogenous
surfactant in CDH is routine in several neonatal centers. No
actual quantitative determination of surfactant in human
CDH lung tissue is available. Taking advantage of access to
fetal human CDH lung tissue samples and lung tissue samples
from fetuses with nonpulmonary diseases used as controls, we
reappraised the question through the determination of the
pulmonary content of major surfactant components, includ-
ing DSPC and SPs, and their accumulation with progressing
pregnancy in human fetuses with CDH. In parallel, we
examined the expression of mesenchymal factors involved
in pulmonary epithelial differentiation and maturation. We
also evaluated these factors in the sheep model with sDH, in
the presence or absence of tracheal occlusion (TO). Also
designated as the PLUG method, TO is a novel approach to
treating CDH lung hypoplasia currently under trial in
humans [35].
Methods
Human Lung Tissue
Postmortem lung tissue samples were obtained at autopsy
after medical termination of pregnancy or neonatal death,
with signed, informed consent from the parents. Terminations
were performed according to the July 1994 French legislation,
and the study was undertaken with the agreement of the
institutional Ethical Committee. The prenatal diagnosis of
CDH was made by echography, and was conﬁrmed by
postmortem examination. Reduced lung weight and consistent
histological appearance conﬁrmed the diagnosis of pulmonary
hypoplasia (lung to body weight ratio , 0.015 before 28 wk of
pregnancy, and , 0.012 thereafter [Table 1]). Fetuses were
checked for other malformations and for the presence or
absence of associated chromosomal abnormality. The lung
ipsilateral to the hernia was used. Lungs from fetuses with
nonpulmonary diseases were used as controls; they appeared
to be histologically normal by postmortem examination and
were not hypoplastic. Detailed clinical data are depicted in
Table 2. Preservation of RNAs in human lung tissue samples
was insufﬁcient and inconsistent, and therefore molecular
study at the pre-translational level could not be performed.
Fetal age (postconception) is used throughout the paper.
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All animal experiments were performed with the author-
ization of the French Ministry of Agriculture. Surgical
procedures have been extensively described elsewhere [36].
Biological samples were from the same animals as those in
previous studies [16,17,37]. In brief, three groups of Pre-Alp
sheep fetuses (full term¼145 d) were studied. The ﬁrst group,
designated the surgical diaphragmatic hernia (sDH) group (n
¼ 5), was obtained by creating a left-sided diaphragmatic
hernia in utero at 85 d of gestation. The second group,
designated the sDH þ TO group (n ¼ 3) was obtained by
creating sDH at 85 d as in the ﬁrst group, then TO at 120 d
with a latex balloon inserted via noninvasive endoscopic
technique. The third group, designated the control group (n¼
6), consisted of twin fetuses that were sham-operated for sDH.
Fetuses were retrieved by cesarean section at 139 d of
gestation, and lung tissue was immediately frozen and stored
at  80 8C.
DSPC Determination
The technique has been described in detail previously [16].
Brieﬂy, lipids were extracted from lung homogenates by
chloroform:methanol:water, 1:2:0.8 (vol/vol/vol). After addi-
tion of a trace amount of labeled dipalmitoylphosphatidyl-
choline (GE Healthcare Life Sciences, https://www1.
gelifesciences.com) for recovery determination, total phos-
phatidylcholine (PC, whole-lipid extract) and DSPC (osmium
tetroxide–treated lipid extract) were separated by thin-layer
chromatography. PC and DSPC were eluted from the gel and
divided into aliquot fractions for scintillation counting and
for phosphate determination after sample mineralization.
Lung DNA
DNA was determined on residual pellet from delipidated
homogenates by the colorimetric diphenylamine method [38].
DPSC was normalized for DNA concentration.
Western Blot Analysis
Human lung tissues were homogenized in RIPA buffer
containing protease inhibitors (Roche Diagnostics, http://www.
roche.com). Proteins (60 lg) were electrophoresed on a 12%
SDS-polyacrylamide gel and transferred onto a polyvinylidene
ﬂuoride membrane (Millipore, http://www.millipore.com),
t h e ns t a i n e dw i t hP o n c e a uS dye (Sigma, http://www.
sigmaaldrich.com). After blocking with 5% nonfat dry milk
in Tris-buffered saline containing 0.05% Tween-20 (TTBS) at
room temperature for 2 h, membranes were exposed for 2 h
to one of the following antibodies: anti-SP-A (gift from M.
Post, Hospital for Sick Children, Toronto, Ontario, Canada),
anti-SP-B (gift from J. A. Whitsett, Cincinnati Children’s
Hospital Medical Center, Cincinnati, Ohio, United States),
anti-proSP-C (Chemicon International, http://www.chemicon.
com), anti-SP-D (BMA Biomedicals, http://www.bma.ch), anti-
thyroid transcription factor 1 (TTF1, Santa Cruz Biotechnol-
ogy, http://www.scbt.com), and anti-NRG1-b1 (R&D Systems,
http://www.rndsystems.com), all diluted in 2% nonfat dry milk
in TTBS, then incubated for 1 h with the appropriate
secondary IgG peroxidase-conjugated antibody. After washing
in TTBS, membranes were incubated for 1 min in chem-
iluminescent detection reagent (ECL, GE Healthcare Life
Sciences), before exposure to Kodak BioMax MS ﬁlm (GE
Healthcare Life Sciences) for 2 min. Densitometry analysis of
blots was performed using NIH image software.
ELISA
KGF and leptin concentrations in human fetal lung tissue
were assessed with commercially sensitive and speciﬁc ELISA
(R&D Systems), following the manufacturer’s instructions,
and normalized to total proteins. The intra-assay coefﬁcient
of variance was less than 5%.
RNA Isolation and Reverse Transcription
Total RNA was extracted from fetal sheep lung tissue using
Trizol reagent (Invitrogen, http://www.invitrogen.com) ac-
Table 1. Characteristics of CDH Fetuses
Number Fetal
Age (wk)
Sex Side Association Liver
Position
Origin Body
Weight (g)
Lung Weight–to–Body
Weight Ratio
1 22 M Left IUGR Thorax Termination 390 0.007
2 22 M Bilateral Polymalformation Thorax Termination 428 ND
3 22 F Left Deletion 8p Thorax Termination 1,050 0.008
4 23 F Left None Thorax Termination 850 0.015
5 25 M Left None Abdomen Termination 1,270 0.008
6 26 M Left None Thorax Termination 1,100 0.003
7 27 M Left None Thorax Termination 1,440 0.007
8 28 M Left Polymalformation Thorax Termination 1,270 0.003
9 30 M Left Duodenal atresia Thorax Postnatal death 2,120 0.006
10 31 F Left Cardiopathy Thorax Termination 1,900 0.004
11 32 F Left None Thorax Termination 1,960 0.006
12 32 ND Left None Thorax Postnatal death ND ND
13 33 F Left Duplication Chromosome 8 Abdomen Termination 1,940 0.012
14 33 M Left Spine Thorax In-utero death 3,300 0.002
15 36 F Left Polymalformation Abdomen Postnatal death 2,800 0.018
16 37 F Right None Thorax Postnatal death 3,350 0.005
Lung specimens were obtained from medical terminations of pregnancy, except for infants 9, 12, 15, and 16 who were born alive and died immediately after birth without possible
resuscitation, and fetus 14, who died in utero. No neonate was treated by extracorporeal membrane oxygenation. None of the mothers received glucocorticoids. All autopsies were
performed within 48 h of death.
ND, not determined.
doi:10.1371/journal.pmed.0040237.t001
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was dissolved in sterile water and quantiﬁed by absorbance at
260 nm (BioPhotometer, Eppendorf, http://www.eppendorf.
de). RNA quality and integrity were conﬁrmed after electro-
phoresis of 1 lg of each sample in 1% agarose gel. RNAs were
reverse-transcribed into cDNAs using 2 lg of total RNA,
Superscript II reverse transcriptase, and random hexamer
primers (Invitrogen), according to the manufacturer’s proto-
col.
Determination of Partial Ovine Neuregulin (NRG) cDNA
Sequence
cDNAs were reverse-transcribed from sheep lung total
RNAs with Superscript II reverse transcriptase and random
hexamer primers (Invitrogen) as above. Ampliﬁcation of the
partial cDNA sequence for NRG was performed using sense
primer 59-TCAGAACTTCGCATTAGCAAAGC-39 (bovine
NRG–speciﬁc sequence) and antisense primer 59-GGGAGTG
GACGTACTGTAGAAGCT-39 (bovine/human NRG–speciﬁc
sequence). Ampliﬁcation was performed through 35 cycles
(1 min at 94 8C, 1 min at 59 8C, and 1 min at 72 8C). The
ampliﬁed sequence was puriﬁed with QIAquick PCR puriﬁ-
cation kit (Qiagen, http://www.qiagen.com) before being
sequenced with an ABI 3130 XL gene analyzer (Applied
Biosystems, http://www.appliedbiosystems.com). The expres-
sion level of the transcripts was studied by real-time PCR in
ovine samples using this sequence; because the transcripts
correspond to common sequences for various NRGs, they are
hereafter designated NRG mRNAs without isoform precision.
Real-Time PCR
A 20-ll mix, containing 12.5 ll of Powerful SYBR Green
PCR Master Mix (Applied Biosystems), 900 nM forward
primer, and 900 nM reverse primer, was prepared for
performing real-time PCR. Primers were designed to be
intron-spanning to avoid co-ampliﬁcation of genomic DNA,
using Primer Express software (Applied Biosystems). Primer
sequences are reported in Table 3. Reverse-transcribed cDNA
(25 ng) was added to the PCR mix to a ﬁnal volume of 25 ll.
Real-time PCR was performed on an ABI Prism 7000 device
(Applied Biosystems) using the following protocol: initial
denaturation (10 min at 95 8C), then a two-step ampliﬁcation
program (15 s at 95 8C followed by 1 min at 60 8C) repeated 40
times. Melt-curve analysis was used to check that a single
speciﬁc ampliﬁed product was generated. Real-time quanti-
ﬁcation was monitored by measuring the increase in
ﬂuorescence caused by the binding of SYBR Green dye to
double-stranded DNA at the end of each ampliﬁcation cycle.
Relative expression was determined using the DDCt (thresh-
old cycle) method of normalized samples (DCt), in relation to
Table 2. Characteristics of Fetuses with Nonpulmonary Diseases Used as Controls
Number Fetal Age (wk) Sex Syndrome Body Weight (g) Lung Weight–to–Body Weight Ratio
1 11 M Norrie syndrome 37 0.030
2 12 F Spine malformation 26 0.038
3 14 M Cardiopathy 115 ND
4 16 F Thanatophoric dwarfism 143 0.026
5 17 F Cardiopathy 235 0.016
6 18 F Chromosomal abnormality 370 0.016
7 21 M Cardiopathy 550 0.028
8 22 M Hydrocepahly 750 0.025
9 22 F Cardiopathy 900 0.029
10 23 M Hydrops 1,100 0.021
11 24 F Brain anomaly 770 0.039
12 24 M Limb anomaly 940 0.027
13 26 M Cardiopathy 1,050 0.026
14 26 F Cardiopathy 1,020 0.024
15 26 F Arthrogryposis 1,100 0.017
16 27 F Pfeiffer’s syndrome 1,300 0.019
17 27 M Cardiopathy 1,580 0.015
18 28 F Limb anomaly 1,640 0.023
19 28 M Brain anomaly 1,430 0.023
20 28 M Trisomy 13 1,630 0.021
21 29 M Tuberous sclerosis complex 1,620 0.029
22 30 M Corpus callosum agenesis 1,850 0.025
23 31 F Cardiopathy 1,720 0.023
24 32 F Hydrocephaly 2,500 0.021
25 32 F Ventriculomegaly 2,500 0.020
26 33 M Trisomy 21 2,450 0.026
27 33 F Corpus callosum agenesis 2,120 0.028
28 33 M Cerebellum agenesia 2,920 0.020
29 33 M Spina bifida 2,100 0.026
30 34 F Gallien vein aneurysm 2,500 0.023
31 35 M Cardiopathy 2,540 0.014
32 36 M Hydrocephaly 2,000 0.020
33 37 F Spina bifida 3,140 0.017
Lung specimens were obtained from medical terminations of pregnancy. None of the mothers received glucocorticoids. All autopsies were performed within 48 h of death.
ND, not determined.
doi:10.1371/journal.pmed.0040237.t002
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manufacturer’s protocol. Each PCR run included a no-
template control and a sample without reverse transcriptase.
All measurements were performed in triplicate.
Statistical Analysis
Relationships between biological variables and fetal age
were analyzed using linear-regression models. When appro-
priate, a quadratic term for time was introduced to ﬁt an
exponential increase with fetal age. Main effects and
interaction terms were tested in order to compare biological
values in human fetuses with CDH versus fetuses with
nonpulmonary diseases used as controls (control fetuses).
Sensitivity analyses were performed when outliers were
present.
For NRG1-b1, SP-A, SP-B, proSP-C, and SP-D, comparison
between human fetuses with CDH and control fetuses was
made using the paired Mann-Whitney U-test. For these
variables, except for NRG1-b1 in control lungs, regression
models were not performed because of the restricted number
of determinations.
For sheep data, multiple group comparisons were made
using the Kruskal-Wallis test, and two-group comparisons
were made using the Mann-Whitney U-test.
A p-value of 0.05 was considered to be the limit of statistical
signiﬁcance. All analyses were performed using R statistical
software (http://cran.r-project.org).
Results
DSPC and SPs in Human Fetal Lungs
DSPC concentration was determined in lung tissue samples
from ten fetuses with CDH, ranging from 24 to 33 wk of
pregnancy, and in 14 age-matched control fetuses, and
normalized for lung DNA concentration. Over the studied
period, DSPC concentration displayed a signiﬁcant exponen-
tial increase with fetal age in control lungs and in CDH lungs
(p-value for quadratic term , 0.01). The evolution of lung
DSPC concentration did not differ signiﬁcantly between
fetuses with CDH and control fetuses when normalized either
to lung wet weight (p-values for groups and interactions .
0.20; Figure 1A) or to lung DNA (p-values for groups and
interactions . 0.25; Figure 1B), with approximately a 5-fold
increase observed at 33 wk in both groups. Similarly, the ratio
of DSPC to total PC increased in both groups at 33 wk (p ,
0.01), which was indicative of an accelerating rate of
maturation, and did not differ among groups (p-values for
groups and interactions . 0.1; Figure 1C). Because of
abnormally high ratios (outliers), one CDH fetus was excluded
from the three analyses and another fetus was excluded from
the DSPC/total PC analysis.
Expression of SP-A, SP-B, SP-D, and proSP-C was evaluated
at the post-translational level by Western blot analysis. Six
pairs of CDH and age-matched control lungs ranging from 28
to 37 wk of pregnancy (i.e., all in saccular-alveolar stages)
were studied comparatively. No obvious difference was
observed for any SP between CDH and control lungs at any
stage (Figure 2A). Densitometry indicated CDH values within
the range of control values (p-values for the four comparisons
. 0.40; Figure 2B). Low molecular weight monomeric forms
of SP-A were detected in signiﬁcant amounts only from 36–37
wk in each group, and were hardly in evidence at younger
stages. Nonreducible di- and trimeric forms were detected at
all stages, with no change with progressing pregnancy. SP-B
was detected early, but was markedly increased also at 36–37
wk in both groups. The only difference between the groups
was a higher SP-B content in the 28-wk fetus with CDH; it
should be emphasized that this fetus also displayed a high
DSPC concentration in Figure 1. ProSP-C showed no marked
developmental changes, and SP-D tended to increase slightly
in both groups.
TTF1 in Human Fetal Lungs
In parallel with SP expression, we evaluated by Western
blot the expression of TTF1, a transcription factor known to
play a major role in various aspects of fetal lung development,
including as a positive regulator of surfactant–protein gene-
promoter activity [39]. Consistent with our ﬁndings on SP
expression, at no stage was any obvious difference found
between fetuses with CDH and control fetuses (Figure 3).
KGF, Leptin, and NRG1-b1 in Human Fetal Lungs
The expression of three growth factors involved in
maturation control of ATII cells, namely KGF, leptin, and
NRG1-b1 proteins, was studied in human lung samples at the
post-translational level. In control lungs, KGF concentration
decreased by about 50% between 14 and 38 wk (r¼ 0.71, p ,
0.001). From 22 wk, when CDH samples were available, CDH
and control lungs displayed statistically different KGF
proﬁles, with a negative slope for control lungs and a positive
slope for CDH samples ( 1.17 versus 2.23, respectively, p ¼
0.03; Figure 4A). Conversely, the leptin proﬁles did not show
Table 3. Primer Sequences for Real-Time PCR
Genes Primer Sequences (59–39) GenBank Accession Numbers
a
KGF Forward: ATCAAAGGAGTGGAAAGTGAATATTACC NM_001009235
Reverse: ATTAATTCTTTGAAGTTGCAGTCTTCGT
Leptin Forward: ATTCCAGCGTGGGCTTCAG AF310264
Reverse: CTGCTGCACATGACCACTAGTG
NRG Forward: CACTGACATGCCAGCCTCAA DQ866826
Reverse: ATGTGGATGAAGAAGTATTTGTTCCTT
18S Forward: AAGTCCCTGCCCTTTGTACACA X03205.1
Reverse: GATCCGAGGGCCTCACTAAAC
All primers were designed to sheep genes.
aGenBank (http://www.ncbi.nlm.nih.gov/Genbank)
doi:10.1371/journal.pmed.0040237.t003
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controls versus 2.60 for CHD samples, p ¼ 0.18; Figure 4B).
Leptin concentration remained at around 10 pg/mg of
protein until 20 wk, and increased linearly from 22 to 38
wk to reach approximately 80–90 pg/mg of protein at the
later stages (Figure 4B). In control lungs, NRG1-b1 concen-
tration remained unchanged until 22 wk, when it then
increased sharply. At 33–35 wk, it reached 7-fold the level
observed at early stages (Figure 5A). Despite the apparent
exponential distribution of the values, it did not display a
signiﬁcant exponential increase (p-value for quadratic term¼
0.25), whereas a signiﬁcant linear correlation was found (r ¼
0.75, p ¼ 0.001). No difference was found for NRG1-b1
between CDH lungs and age-matched control lungs, as
evaluated in seven pairs aged 23 to 36 wk (p¼0.58; Figure 5B).
KGF, Leptin, and NRG in the Ovine sDH Model, and Effects
of TO
The three growth factors were analyzed in fetal sheep lungs
at the pre-translational level by real-time PCR. KGF mRNA
was signiﬁcantly decreased in the sDH group, and its
expression level was partially restored by TO (Figure 6A).
The leptin mRNA level was not signiﬁcantly affected by sDH,
but TO enhanced expression to 3.5 times the control level
(Figure 6B). Determination of the partial sequence of ovine
NRG did not allow the NRG1-b1 mRNA isoform to be
selectively determined by real time PCR because the partial
sequence is common to various isoforms. The mRNA level
determined using this sequence and designated NRG was
diminished to 42% of control value in the sDH group, and
was restored to control level in the sDH þ TO group (Figure
6C).
Discussion
A persistent question regarding the care of neonates with
CDH is whether these infants are effectively surfactant
deﬁcient. The question of whether to administer surfactant
to infants born with CDH is not trivial, as this therapy can
transiently compromise gas exchange. Information about
surfactant status in humans is limited, has been obtained by
indirect approaches, and has remained controversial. We
reappraised the question through the ontogenetic study of
surfactant directly in CDH lung tissue samples. We showed
that, contrary to current opinion, surfactant accumulation
occurs in CDH lungs at the normal time and rate.
The postmortem collection of tissue samples was a
limitation of this study and prevented us from studying
expression at the pre-translational level. Investigations in
humans also raise the question of control appropriateness,
since only lung samples from subjects with nonpulmonary
diseases could be used as controls. A previous demonstration
of the differences between CDH and control lungs, consider-
ing other parameters, nevertheless validated the approach [40].
Developmental changes in the concentration of DSPC, the
major surfactant component, were identical in CDH and
control lung tissue samples, with a marked increase in late
pregnancy. Surfactant-storing lamellar bodies appear in the
human fetus at around 20 wk [41]. The rise observed for
DSPC at around 33 wk therefore corresponds to an increased
rate of accumulation, not to the initiation of surfactant
synthesis. Although DSPC is present also in other lung cell
Figure 1. DSPC in Human Fetal Lungs
DSPC was normalized to lung wet weight (ww) (A) and lung DNA (B), and
expressed as a ratio of DSPC to total PC (i.e., DSPC plus unsaturated PC)
(C). A rise in DSPC concentration and in the ratio of DSPC to total PC,
which is indicative of an enhanced rate of surfactant accumulation, was
observed at fetal age 32–33 wk in CDH as well as in control fetal lungs.
There were no differences in the data between the groups, whatever the
considered fetal age. DSPC displayed the same exponential increase in
control lungs and CDH lungs with fetal age (p-value for quadratic term ,
0.01).
doi:10.1371/journal.pmed.0040237.g001
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and in the ratio of DSPC to total PC is illustrative of
increasing surfactant content. It is therefore of particular
signiﬁcance that these parameters increased at the same fetal
age in control and CDH lungs.
Also indicative of alveolar cell maturation is the increase in
both SP-A and SP-B that was observed at the same time in
both groups. Although the available amount of tissue from
the 37-wk CDH lung was not sufﬁcient for studying DSPC
concentration, our results indicate similar timing for DSPC
and SP accumulation. ProSP-C is of particular interest
because, contrary to other SPs that are also expressed in
bronchiolar Clara cells, it is a speciﬁc marker of ATII cells
[42]. The comparable concentrations of proSP-C in CDH and
non-CDH lungs therefore indicate similar ATII cell-matura-
tion status in both instances. No developmental change was
observed for proSP-C because it does not accumulate in the
developing lung, unlike mature proteins [43]. Considering the
role of TTF1 as a transcription regulator of SPs [39], the
absence of any change in SP content is fully consistent with
unchanged TTF1 protein abundance between CDH and
control lungs, and with the comparable staining for TTF1
that has been observed previously [44].
Previous investigations about surfactant status in CDH
have led to controversial data, which have left inconclusive
the question of primary surfactant deﬁciency. Some studies
that appear consistent with the present ﬁndings showed no
change in surfactant content of amniotic ﬂuid [28], or in
bronchoalveolar lavage [29], from infants with CDH, whereas
others reported decreased surfactant in amniotic ﬂuid [25],
or reduced levels of DSPC and SP-A in tracheal aspirates,
from ventilated infants with CDH [26]. The present study,
which, to our knowledge, is the ﬁrst to appraise the question
through the determination of surfactant in human lung
tissue, indicates normal timing and a normal rate of
surfactant accumulation in the CDH lung ipsilateral to the
hernia.
There are several possible explanations for the discrep-
ancies highlighted by previous investigations. First, although
lung concentrations of surfactant components are normal,
the total lung surfactant content is decreased in the CDH
lung as a consequence of lung hypoplasia. This may account
for the decreased surfactant levels measured in amniotic or
lavage ﬂuids. Nevertheless, the amount of surfactant is
probably appropriate for lung size and alveolar surface area.
Second, ventilation may have inﬂuenced surfactant compo-
sition and/or concentration. It has indeed been reported that
ventilation alters alveolar surfactant in rat pups [45] and that
ventilation strategies interfere differentially with surfactant
metabolism in injured lungs [46]. Moreover, DSPC turnover
was found to be more rapid in infants with CDH, presumably
reﬂecting an increase in catabolism or recycling of DSPC [27].
Together, these factors may lead to a secondary surfactant
deﬁciency acquired after birth, which may in turn account for
a reduced tracheal aspirate content in CDH despite a normal
amniotic ﬂuid content.
Figure 2. SPs in Human Fetal Lungs
(A) Western blots: Samples were electrophoresed by SDS-PAGE, trans-
ferred, and successively incubated with specific anti-SP antibodies. (B)
Densitometric analysis normalized by Ponceau S for gel loading (arbitrary
units). SPs were detected at all stages. SP-A monomers were extremely
faint before 36 wk, when they increased sharply (A) resulting in an
increase in total amount (B). SP-B also increased markedly at 36–37 wk,
ProSP-C did not display developmental changes, and SP-D showed a
weak increase (A, B). There were no obvious differences between CDH
and control lungs for any SP, with developmental changes occurring at
the same fetal ages, the only exception being presentation of a high SP-B
level in one CDH fetus, aged 28 wk.
doi:10.1371/journal.pmed.0040237.g002
Figure 3. TTF1 Protein in Human Fetal Lungs
Western blot was performed in lung samples of fetuses with CDH (lanes
labeled H) and in fetuses with nonpulmonary diseases used as controls
(lanes labeled C) at four fetal ages (Ponceau S stain was used as loading
control). No differences were observed between CDH fetuses and age-
matched control fetuses.
doi:10.1371/journal.pmed.0040237.g003
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deﬁciency has been repeatedly reported in the sheep [14–17]
and rat [18–20] models of CDH. To further explore under-
lying mechanisms that may account for this discrepancy, we
investigated comparatively in human and ovine lungs the
expression of paracrine factors known to control ATII cell
maturation. We used samples from the same sheep lungs as in
previous studies [16–17]. A wide array of growth factors has
been reported to stimulate surfactant production. We studied
three potent stimulating factors—KGF, leptin, and NRG1-
b1—which are all secreted by interstitial cells under the
regulation of glucocorticoids, the hormones that primarily
control surfactant maturation. To our knowledge, the present
investigation is the ﬁrst to document the levels of these
stimulating factors over time during development of the
human fetal lung. KGF displayed a higher concentration in
the early-canalicular stage, coincidental with the time of ATII
cell differentiation [41], than in the late-canalicular and
Figure 4. KGF and Leptin in Human Fetal Lungs
ELISAs were performed on the lungs of 20 fetuses with nonpulmonary
diseases used as controls, ranging from 14 to 37 wk of pregnancy, and
on 11 fetuses with CDH ranging from 22 to 37 wk. Individual values are
shown. Linear regression was performed for the period 22–37 wk when
samples were available for both groups. KGF (A) displayed different
profiles according to the groups concerned, with a negative slope for
control lungs and a positive slope for CDH lungs ( 1.17 versus 2.23,
respectively, p¼0.03). Leptin assay (B) evidenced little change in control
lungs before 22 wk; a similar linear increase occurred between 22 and 37
wk with no difference between groups (slope ¼ 4.82 versus 2.60 for
controls and CHD samples, respectively, p ¼ 0.18).
doi:10.1371/journal.pmed.0040237.g004
Figure 5. NRG1-b1 in Human Fetal Lungs
(A) Developmental changes in control lungs were studied from 11 to 36
wk of pregnancy. Upper: representative Western blot. A 45-kDa band
corresponds to NRG1-b1 (the 55-kDa band is nonspecific [61]). Lower:
densitometric analysis (arbitrary units [a.U.]) in 15 individuals showing a
significant linear increase (r ¼ 0.75, p ¼ 0.001).
(B) Comparative study in seven pairs of age-matched CDH (lanes labeled
H) and control (lanes labeled C) lungs. Upper: representative Western
blot. Lower: densitometric analysis; there was no significant difference in
expression level between CDH and control lungs (p ¼ 0.58).
doi:10.1371/journal.pmed.0040237.g005
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consistent with the prominent role ascribed to KGF in ATII
cell differentiation [47]. Although lower, the sustained level in
late pregnancy is nevertheless consistent with the stimulating
activity of KGF on surfactant synthesis in fetal [9] and adult
[48] type II cells. Interestingly, leptin and NRG1-b1 started
increasing sharply in the human lung from about 25 wk of
pregnancy, to reach their highest levels when the rate of
surfactant accumulation was maximal. This is in keeping with
previous animal investigations that have led the authors to
consider these mediators as major paracrine regulators of
surfactant synthesis [11,13]. Also in agreement is the
observation of increased NRG1-b1 expression in human fetal
lung explants maturing in vitro, and of enhanced surfactant
synthesis by exogenous NRG1-b1 in these explants [12].
Fully consistent with ﬁndings about surfactant compo-
nents, we observed no decrease for either factor in CDH
lungs as compared with control lungs. KGF concentrations
were even slightly higher in CDH lungs at late-gestational
stages, although this difference cannot readily be explained.
These data suggest that the lung hypoplasia associated with
CDH does not interfere with the mesenchymal–epithelial
interactions that control alveolar cell maturation. On the
whole, human CDH lungs did not exhibit a trend toward a
decrease in contents, or a delay in developmental changes for
any of the studied parameters, including surfactant compo-
nents and surfactant maturation factors.
In contrast with human lungs, KGF and NRG transcripts
were decreased in the ovine model of CDH. With regard to
KGF, this is in agreement with previous reports in the same
model [49] and in the nitrofen model [50]. To our knowledge,
NRG and leptin transcripts had not been investigated
previously. Decreased expression of KGF and NRG is likely
to be related to the surfactant deﬁcit reported in the animal
models. Surprisingly, TO, which is known to induce a
dramatic surfactant deﬁcit, either in the presence [16] or in
the absence [51] of diaphragmatic hernia, restored KGF and
NRG expression. TO also strongly up-regulated the expres-
sion of leptin. Surfactant reduction appears to be the
consequence of massive TO-enhanced transdifferentiation
of ATII into ATI cells [22,37,52]. TO-enhanced expression of
KGF, leptin, and NRG was therefore insufﬁcient to counter-
act this effect.
Although they have provided considerable insight into the
understanding of the disease, animal models of CDH have
shown several limitations with respect to their relevance to
the human condition [53]. The present study indicates that
the surfactant status of the human fetus with CDH could not
be inferred from animal ﬁndings. The discordance between
human CDH and the ovine model may result from the timing
of the insult that occurs later in lung development in lambs
and from the different degree of lung morphological
maturity at full term that is more advanced in the lamb than
in humans. With regard to the nitrofen model, it should be
emphasized that lung hypoplasia and immaturity also occur
in pups that do not develop CDH. The deﬁcit in surfactant
components, when observed, could therefore result from
pulmonary toxic effects of nitrofen, including impairment of
TTF1 expression, which was found to be down-regulated by
nitrofen in fetal rat lungs independently of the presence of
CDH [54], and also in the lung epithelial H-441 cell line [55].
Although exogenous surfactant was formerly reported to
Figure 6. KGF, Leptin, and NRG mRNAs in Ovine Fetal Lungs
RT followed by real-time PCR analysis; mean 6 standard error of the
mean on six, five, and three individual samples, respectively, in sham-
operated control fetuses (C), in a surgical model of CDH (sDH), and in
sDH with subsequent tracheal occlusion (sDH þ TO). The Kruskal-Wallis
test was used for multiple-group comparison, with two-group compar-
isons made by Mann-Whitney U-test (*p , 0.05 and **p , 0.01).
(A) KGF mRNA level was reduced by half by sDH and was partially
restored by sDH þ TO.
(B) Leptin mRNA was not affected by sDH, whereas TO enhanced
expression to 3.5 times the control level.
(C) NRG mRNA level was decreased by 60% by sDH and was restored by
sDH þ TO.
doi:10.1371/journal.pmed.0040237.g006
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more recent multicentric study evidenced no beneﬁt [34],
consistent with our ﬁndings of normal surfactant content.
Furthermore, another recent investigation concluded that
late prenatal corticosteroids provide no signiﬁcant beneﬁt to
fetuses with CDH [56], and this ﬁnding is consistent with a
normal maturational rate and normal level of corticosteroid-
dependent maturation factors as reported in this paper. By
contrast, the reported efﬁcacy of glucocorticoid therapy [57]
or surfactant therapy [58] in neonatal lambs with sDH is
consistent with their surfactant deﬁciency. However, the
negative effect of TO on surfactant content [59], and the
positive effects of combining maternal glucocorticoid ther-
apy, surfactant supplementation, and TO in sheep [60],
suggest possible suitability of these treatments in the care
of infants treated by the PLUG method.
In conclusion, the present data challenge the paradigm that
the human CDH lung is surfactant deﬁcient as compared with
the age-matched normal lung. CDH does not appear to
interfere with surfactant accumulation, which occurs with
normal timing and remains proportional to lung weight.
Prophylactic administration of surfactant at birth in infants
with CDH may therefore be useless. However, before
surfactant administration can be ruled out as a potential
therapy for CDH, a prospective randomized trial that also
takes into account the severity of the underlying lung
hypoplasia and the gestational age at delivery is necessary.
Supporting Information
Alternative Language Abstract S1 Translation of the Abstract into
French by Jacques Bourbon
Found at doi:10.1371/journal.pmed.0040237.sd001 (30 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
ber for the sense primer 59-TCAGAACTTCGCATTAGCAAAGC-39,
bovine NRG–speciﬁc sequence, is NM174128. The GenBank accession
number for the antisense primer 59-GGGAGTGGACGTACTGTA
GAAGCT-39 is NM174128 for the bovine NRG–speciﬁc sequence and
NM013962 for the human NRG–speciﬁc sequence.
Acknowledgments
OB was supported by a Doctoral Fellowship grant from the Fondation
pour la Recherche Me ´dicale.
Author contributions. AB and JB designed the study. OB, AB, BCH,
MLFM, and JB performed the experiments. CE performed the
statistical analyses. JM coordinated the autopsy organization and
the collection of autopsy materials. OB, AB, BCH, CE, and JB
contributed to writing the paper.
References
1. Stege G, Fenton A, Jaffray B (2003) Nihilism in the 1990s: The true
mortality of congenital diaphragmatic hernia. Pediatrics 112: 532–535.
2. Moya FR, Lally KP (2005) Evidence-based management of infants with
congenital diaphragmatic hernia. Semin Perinatol 29: 112–117.
3. George DK, Cooney TP, Chiu BK, Thurlbeck WM (1987) Hypoplasia and
immaturity of the terminal lung unit (acinus) in congenital diaphragmatic
hernia. Am Rev Respir Dis 136: 947–950.
4. Johansson J, Curstedt T (1997) Molecular structures and interactions of
pulmonary surfactant components. Eur J Biochem 244: 675–693.
5. Kingma PS, Whitsett JA (2006) In defense of the lung: Surfactant protein A
and surfactant protein D. Curr Opin Pharmacol 6: 277–283.
6. Serrano AG, Perez-Gil J (2006) Protein-lipid interactions and surface
activity in the pulmonary surfactant system. Chem Phys Lipids 141: 105–
118.
7. Mendelson CR, Boggaram V (1991) Hormonal control of the surfactant
system in fetal lung. Annu Rev Physiol 53: 415–440.
8. Post M, Floros J, Smith BT (1984) Inhibition of lung maturation by
monoclonal antibodies against ﬁbroblast-pneumonocyte factor. Nature
308: 284–286.
9. Chelly N, Mouhieddine-Gueddiche OB, Barlier-Mur AM, Chailley-Heu B,
Bourbon JR (1999) Keratinocyte growth factor enhances maturation of
fetal rat lung type II cells. Am J Respir Cell Mol Biol 20: 423–432.
10. Chelly N, Henrion A, Pinteur C, Chailley-Heu B, Bourbon JR (2001) Role of
keratinocyte growth factor in the control of surfactant synthesis by fetal
lung mesenchyme. Endocrinology 142: 1814–1819.
11. Torday JS, Sun H, Wang L, Torres E, Sunday ME, et al. (2002) Leptin
mediates the parathyroid hormone-related protein paracrine stimulation of
fetal lung maturation. Am J Physiol Lung Cell Mol Physiol 282: L405–L410.
12. Patel NV, Acarregui MJ, Snyder JM, Klein JM, Sliwkowski MX, et al. (2000)
Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a
role in human lung development in vitro. Am J Respir Cell Mol Biol 22:
432–440.
13. Dammann CE, Nielsen HC, Carraway KL 3rd (2003) Role of neuregulin-1
beta in the developing lung. Am J Respir Crit Care Med 167: 1711–1716.
14. Glick PL;, Stannard VA, Leach CL, Rossman J, Hosada Y, et al. (1992)
Pathophysiology of congenital diaphragmatic hernia II: The fetal lamb
CDH model is surfactant deﬁcient. J Pediatr Sug 27: 382–387.
15. Wilcox DT, Glick PL, Karamanoukian HL, Holm BA (1997) Contributions
by individual lungs to the surfactant status in congenital diaphragmatic
hernia. Pediatr Res 41: 686–691.
16. Benachi A, Chailley-Heu B, Delezoide AL, Dommergues M, Brunelle F, et al.
(1998) Lung growth and maturation after tracheal occlusion in diaphrag-
matic hernia. Am J Respir Crit Care Med 157: 921–927.
17. Benachi A, Chailley-Heu B, Barlier-Mur AM, Dumez Y, Bourbon J (2002)
Expression of surfactant proteins and thyroid transcription factor 1 in an
ovine model of congenital diaphragmatic hernia. J Pediatr Surg 37: 1393–
1398.
18. Suen HC, Catlin EA, Ryan DP, Wain JC, Donahoe PK (1993) Biochemical
immaturity of lungs in congenital diaphragmatic hernia. J Pediatr Surg 28:
471–475.
19. Mysore MR, Margraf LR, Jaramillo MA, Breed DR, Chau VL, et al. (1998)
Surfactant protein A is decreased in a rat model of congenital
diaphragmatic hernia. Am J Respir Crit Care Med. 157: 654–657.
20. Thebaud B, Barlier-Mur AM, Chailley-Heu B, Henrion-Caude A, Tibboel D,
et al. (2001) Restoring effects of vitamin A on surfactant synthesis in
nitrofen-induced congenital diaphragmatic hernia in rats. Am J Respir Crit
Care Med 164: 1083–1089.
21. Brandsma AE, Tibboel D, Vulto IM, Egberts J, Ten Have-Opbroek AA
(1993) Ultrastructural features of alveolar epithelial cells in the late fetal
pulmonary acinus: A comparison between normal and hypoplastic lungs
using a rat model of pulmonary hypoplasia and congenital diaphragmatic
hernia. Microsc Res Tech 26: 389–399.
22. Van Tuyl M, Blommaart PE, Keijzer R, Wert SE, Ruijter JM, et al. (2003)
Pulmonary surfactant protein A, B, and C mRNA and protein expression in
the nitrofen-induced congenital diaphragmatic hernia rat model. Pediatr
Res 54: 641–652.
23. Chapin CJ, Ertsey R, Yoshizawa J, Hara A, Sbragia L, et al. (2005) Congenital
diaphragmatic hernia, tracheal occlusion, thyroid transcription factor-1,
and fetal pulmonary epithelial maturation. Am J Physiol Lung Cell Mol
Physiol 289: L44–L52.
24. Davey MG, Biard JM, Robinson L, Tsai J, Schwarz U, et al. (2005) Surfactant
protein expression is increased in the ipsilateral but not contralateral lungs
of fetal sheep with left-sided diaphragmatic hernia. Pediatr Pulmonol 39:
359–367.
25. Moya FR, Thomas VL, Romaguera J, Mysore MR, Maberry M, et al. (1995)
Fetal lung maturation in congenital diaphragmatic hernia. Am J Obstet
Gynecol 173: 1401–1405.
26. Cogo PE, Zimmermann LJ, Rosso F, Tormena F, Gamba P, et al. (2002)
Surfactant synthesis and kinetics in infants with congenital diaphragmatic
hernia. Am J Respir Crit Care Med 166: 154–158.
27. Cogo PE, Zimmermann LJ, Verlato G, Midrio P, Gucciardi A, et al. (2004) A
dual stable isotope tracer method for the measurement of surfactant
disaturated-phosphatidylcholine net synthesis in infants with congenital
diaphragmatic hernia. Pediatr Res 56: 184–190.
28. Sullivan KM, Hawgood S, Flake AW, Harrison MR, Adzick NS (1994)
Amniotic ﬂuid phospholipid analysis in the fetus with congenital
diaphragmatic hernia. J Pediatr Surg 29: 1020–1023.
29. Ijsselstijn H, Zimmermann LJ, Bunt JE, de Jongste JC, Tibboel D (1998)
Prospective evaluation of surfactant composition in bronchoalveolar
lavage ﬂuid of infants with congenital diaphragmatic hernia and of age-
matched controls. Crit Care Med 26: 573–580.
30. Asabe K, Tsuji K, Handa N, Kurosaka N, Kajiwara M (1997) Immunohis-
tochemical distribution of surfactant apoprotein-A in congenital dia-
phragmatic hernia. J Pediatr Surg 32: 667–672.
31. Arias F, Pineda J, Johnson LW (1979) Changes in human amniotic ﬂuid
lecithin/sphingomyelin ratio and dipalmitoyl lecithin associated with
maternal betamethasone therapy. Am J Obstet Gynecol 133: 894–898.
32. Bos AP, Tibboel D, Hazebroek FW, Molenaar JC, Lachmann B, et al. (1991)
Surfactant replacement therapy in high-risk congenital diaphragmatic
hernia. Lancet 337: 913–915.
33. Glick PL, Leach CL, Besner GE, Egan EA, Morin FC, et al. (1992)
PLoS Medicine | www.plosmedicine.org July 2007 | Volume 4 | Issue 7 | e237 1214
Surfactant in Human CDHPathophysiology of congenital diaphragmatic hernia. III: Exogenous surfac-
tant therapy for the high-risk neonate with CDH. J Pediatr Surg 27: 866–869.
34. Lally KP, Lally PA, Langham MR, Hirschl R, Moya FR, et al. (2004)
Surfactant does not improve survival rate in preterm infants with
congenital diaphragmatic hernia. J Pediatr Surg 39: 829–833.
35. Jani J, Gratacos E, Greenough A, Piero JL, Benachi A, et al. (2005)
Percutaneous fetal endoscopic tracheal occlusion (FETO) for severe left-
sided congenital diaphragmatic hernia. Clin Obstet Gynecol 48: 910–922.
36. Benachi A, Dommergues M, Delezoide AL, Bourbon J, Dumez Y (1997)
Tracheal obstruction in experimental diaphragmatic hernia: An endo-
scopic approach in the fetal lamb. Prenat Diagn 17: 629–634.
37. Benachi A, Delezoide AL, Chailley-Heu B, Preece M, Bourbon JR, et al.
(1999) Ultrastructural evaluation of lung maturation in a sheep model of
diaphragmatic hernia and tracheal occlusion. Am J Respir Cell Mol Biol 20:
805–812.
38. Burton K (1956) A study of the conditions and mechanism of the
diphenylamine reaction for the colorimetric estimation of deoxyribonu-
cleic acid. Biochem J 62: 315–323.
39. Boggaram V (2003) Regulation of lung surfactant protein gene expression.
Front Biosci 8: D751–D764.
40. Boucherat O, Benachi A, Barlier-Mur AM, Franco-Montoya ML, Martinovic
J, et al. (2007) Decreased lung ﬁbroblast growth factor 18 and elastin in
congenital diaphragmatic hernia and models. Am J Respir Crit Care Med
175: 1066–1077.
41. Dechelotte P, Kantelip B, Fonck-Cussac Y, Delage J (1983) Electron
microscopy study of the development of the pulmonary alveolus in the
human fetus. Ann Pathol 3: 51–58.
42. Kalina M, Mason RJ, Shannon JM (1992) Surfactant protein C is expressed
in alveolar type II cells but not in Clara cells of rat lung. Am J Respir Cell
Mol Biol 6: 594–600.
43. Solarin KO, Ballard PL, Guttentag SH, Lomax CA, Beers MF (1997)
Expression and glucocorticoid regulation of surfactant protein C in human
fetal lung. Pediatr Res 42: 356–364.
44. Hosgor M, Ijzendoorn Y, Mooi WJ, Tibboel D, De Krijger RR (2002) Thyroid
transcription factor-1 expression during normal human lung development
and in patients with congenital diaphragmatic hernia. J Pediatr Surg 37:
1258–1262.
45. Martinez F, Lewis J, Copland I, Engelberts D, Kavanagh BP, et al. (2004)
Mechanical ventilation effect on surfactant content, function, and lung
compliance in the newborn rat. Pediatr Res 56: 19–25.
46. Ito Y, Veldhuizen RA, Yao LJ, McCaig LA, Bartlett AJ, et al. (1997)
Ventilation strategies affect surfactant aggregate conversion in acute lung
injury. Am J Respir Crit Care Med 155: 493–499.
47. Shannon JM, Gebb SA, Nielsen LD (1999) Induction of alveolar type II cell
differentiation in embryonic tracheal epithelium in mesenchyme-free
culture. Development 126: 1675–1688.
48. Yano T, Mason RJ, Pan T, Deterding RR, Nielsen LD, et al. (2000) KGF
regulates pulmonary epithelial proliferation and surfactant protein gene
expression in adult rat lung. Am J Physiol Lung Cell Mol Physiol 279:
L1146–L1158.
49. McCabe AJ, Carlino U, Holm BA, Glick PL (2001) Upregulation of
keratinocyte growth factor in the tracheal ligation lamb model of
congenital diaphragmatic hernia. J Pediatr Surg 36: 128–132.
50. Teramoto H, Yoneda A, Puri P (2003) Gene expression of ﬁbroblast growth
factors 10 and 7 is downregulated in the lung of nitrofen-induced
diaphragmatic hernia in rats. J Pediatr Surg 38: 1021–1024.
51. Flecknoe SJ, Wallace MJ, Harding R, Hooper SB (2002) Determination of
alveolar epithelial cell phenotypes in fetal sheep: Evidence for the
involvement of basal lung expansion. J Physiol 542: 245–253.
52. Piedboeuf B, Laberge JM, Ghitulescu G, Gamache M, Petrov P, et al. (1997)
Deleterious effect of tracheal obstruction on type II pneumocytes in fetal
sheep. Pediatr Res 41: 473–479.
53. Wilcox DT, Irish MS, Holm BA, Glick PL (1996) Animal models in
congenital diaphragmatic hernia. Clin Perinatol 23: 813–822.
54. Losada A, Tovar JA, Xia HM, Diez-Pardo JA, Santisteban P (2000) Down-
regulation of thyroid transcription factor-1 gene expression in fetal lung
hypoplasia is restored by glucocorticoids. Endocrinology 141: 2166–2173.
55. Losada A, Xia H, Migliazza L, Diez-Pardo JA, Santisteban P, et al. (1999)
Lung hypoplasia caused by nitrofen is mediated by down-regulation of
thyroid transcription factor TTF-1. Pediatr Surg Int 15: 188–191.
56. Lally KP, Bagolan P, Hosie S, Lally PA, Stewart M, et al. (2006)
Corticosteroids for fetuses with congenital diaphragmatic hernia: Can we
show beneﬁt? J Pediatr Surg 41: 668–674.
57. Schnitzer JJ, Hedrick HL, Pacheco BA, Losty PD, Ryan DP, et al. (1996)
Prenatal glucocorticoid therapy reverses pulmonary immaturity in
congenital diaphragmatic hernia in fetal sheep. Ann Surg 224: 430–439.
58. O’Toole SJ, Karamanoukian HL, Sharma A, Morin FC 3rd, Holm BA, et al.
(1996) Surfactant rescue in the fetal lamb model of congenital diaphrag-
matic hernia. J Pediatr Surg 31: 1105–1109.
59. Bratu I, Flageole H, Laberge JM, Possmayer F, Harbottle R, et al. (2001)
Surfactant levels after reversible tracheal occlusion and prenatal steroids in
experimental diaphragmatic hernia. J Pediatr Surg 36: 122–127.
60. Davey MG, Danzer E, Schwarz U, Adzick NS, Flake AW, et al. (2006)
Prenatal glucocorticoids and exogenous surfactant therapy improve
respiratory function in lambs with severe diaphragmatic hernia following
fetal tracheal occlusion. Pediatr Res 60: 131–135.
61. Herrlich A, Leitch V, King LS (2004) Role of proneuregulin 1 cleavage and
human epidermal growth factor receptor activation in hypertonic
aquaporin induction. Proc Natl Acad Sci USA 101: 15799–15804.
Editors’ Summary
Background. Congenital diaphragmatic hernia (CDH), a fetal malforma-
tion in which the abdominal organs are displaced into the chest cavity,
occurs in approximately one out of 3,000 live births and accounts for
approximately 8% of major birth defects. The displaced lungs tend to be
underdeveloped at birth, and decreased lung function is a major cause of
sickness and death in affected babies.
Pulmonary surfactant, a substance naturally produced by cells in the
lungs in the weeks before birth, is necessary for normal breathing.
Surfactant acts to keep the walls of the lung’s airspaces from collapsing
onto each other, much as detergent can keep the walls of a moist plastic
bag from sticking together.
Why Was This Study Done? The specific aspects of lung immaturity that
cause decreased function in babies with CDH are not fully understood. In
particular, it has been unclear whether abnormally low levels of
pulmonary surfactant contribute to the lung problems caused by CDH.
Some studies in sheep or rat models of CDH have found that surfactant
levels are abnormally low, while others have found normal or even
increased levels of surfactant. Studies in human CDH have also shown
controversial results, and few have investigated surfactant production in
lung tissue itself.
Doctors can artificially increase babies’ pulmonary surfactant levels if
necessary through the instillation of exogenous surfactant material, but
doing so involves some risk. This is a routine treatment with
demonstrated benefit in premature neonates with normal, although
not fully developed, lungs. Pulmonary surfactant is sometimes given also
to babies with CDH, but in this particular instance, the benefit of this
practice is unclear. The authors of this study wanted to determine
whether or not babies with CDH really have low levels of pulmonary
surfactant.
What Did the Researchers Do and Find? The researchers performed
autopsies to study lung tissue from human fetuses in pregnancies that
ended in fetal death, were terminated for medical reasons, or resulted in
death immediately after birth. They compared surfactant production in
16 fetuses with CDH to that in 33 fetuses with conditions not involving
the lungs. They found that, taking fetal age into account, surfactant was
present at similar levels in lung tissue from both groups, and that
production of surfactant components and other factors involved in lung
maturation was not delayed in CDH.
The researchers also studied sheep fetuses with surgically induced
CDH, a model that has been used in the past to study lung development
in CDH. In contrast with the findings in humans, they found that factors
stimulating surfactant production were decreased in sheep with
surgically induced CDH.
What Do These Findings Mean? These findings suggest that surfactant
deficiency is not a major contributor to lung problems in babies with
CDH, and that further clinical research may be appropriate to determine
whether administering surfactant to these babies is beneficial. The
findings also suggest that commonly used animal models of CDH may be
of limited relevance to human CDH.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040237.
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